Skip to search formSkip to main contentSkip to account menu

Campath

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

alemtuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas
The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable. Therefore, there is… 
Review
2009
Review
2009
Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic…
Abstract 537 Introduction: Single-arm pilot and Phase II trial data suggested that the combination of fludarabine and alemtuzumab… 
2008
2008
Clinical course of kidney transplant patients with acute rejection and BK virus replication following Campath therapy
Abstract:  Background:  Kidney transplant recipients with active BK virus (BKV) replication are generally treated with reduction… 
2006
2006
Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
2005
2005
The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors.
BACKGROUND AND OBJECTIVES Primary graft failure is a serious complication following hematopoietic cell transplants, particularly… 
2005
2005
Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
Alemtuzumab (Campath 1H) is a recombinant DNA derived humanized monoclonal antibody which targets CD52 antigens on B and T cells… 
Review
2005
Review
2005
Microbiologic consequences of new approaches to managing hematologic malignancies.
Opportunistic infections have always been pitfalls on the road of progress in the treatment of diseases that are accompanied by… 
Review
2004
Review
2004
Treatment of refractory autoimmune diseases with ablative immunotherapy.
2004
2004
Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia
Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia 
2004
2004
Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.
Peripheral (mature) T-cell lymphomas (PTCL) are represented by distinct lymphoma entities, many of which with a rather… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)